Treatment of Portopulmonary Hypertension in WHO Functional Class IV or When Low-Risk Criteria Are Not Met

Portopulmonary hypertension at WHO functional class IV — or when pulmonary haemodynamics do not satisfy low-risk criteria — identifies a high-severity sub-population requiring a distinct, escalated treatment strategy.

Clinical scenario This protocol applies to patients with WHO functional class IV portopulmonary hypertension, or to any patient with pulmonary hypertension not meeting low-risk criteria. This classification indicates significant functional impairment and haemodynamic compromise that demands targeted intervention.

Treatment approach — partial overview Management in this setting involves prostacyclin agonist (prostanoid) therapy used as bridge treatment, with supportive measures addressing oxygenation and volume overload given alongside. The complete agent selection, sequencing, and full regimen are available in the structured protocol.

Treatment targets Clinical goals include reduction of mean pulmonary arterial pressure and pulmonary vascular resistance, improvement in WHO functional class, and increased exercise tolerance assessed by the 6-minute walking test.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/TXD.0000000000001517

The prostacyclin agonists (prostanoids) are reserved for patients with a type IV functional class according to the World Health Organization or any patient with PH not meeting low-risk criteria.

They can be used as bridge therapy for patients on the transplant list.

Supplementary oxygen is recommended for patients with oxygen saturation <89%, as per ILTS guidelines.

Diuretics, which are frequently used for the treatment of portal hypertension, are important in the management of PH and volume overload.

Generally, prostacyclin agonists have shown an improvement in pulmonary hemodynamics, functional class, and the ability to exercise.

It also appears to significantly improve pulmonary hemodynamics for patients with moderate to severe PAH and reduce the mean arterial pulmonary pressure and PVR.

View source ↗